Cardiol Therapeutics Inc.
CRDL
$1.17
$0.0857.87%
| Weiss Ratings | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.22 | |||
| Price History | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.27% | |||
| 30-Day Total Return | -14.34% | |||
| 60-Day Total Return | -19.10% | |||
| 90-Day Total Return | -38.03% | |||
| Year to Date Total Return | -14.96% | |||
| 1-Year Total Return | -28.53% | |||
| 2-Year Total Return | 118.04% | |||
| 3-Year Total Return | -15.58% | |||
| 5-Year Total Return | -40.26% | |||
| 52-Week High % Change | -65.38% | |||
| 52-Week Low % Change | 5.88% | |||
| Price | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.12 | |||
| 52-Week Low Price | $1.02 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Jun 12, 2024 | |||
| Valuation | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 88.90M | |||
| Enterprise Value | 78.00M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.39 | |||
| Earnings Per Share Growth | 20.72% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 9.82 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.17 | |||
| Enterprise Value/EBITDA (TTM) | -2.78 | |||
| Enterprise Value/EBIT | -2.77 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 69.84M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 289 910 0850 | |||
| Address | 2265 Upper Middle Road East Oakville, ON L6H 0G5 | |||
| Website | www.cardiolrx.com | |||
| Country | Canada | |||
| Year Founded | 2017 | |||
| Profitability | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -78.58% | |||
| Return on Equity | -- | |||
| Income Statement | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -28.03M | |||
| EBIT (TTM) | -28.16M | |||
| Net Income (TTM) | -26.57M | |||
| Net Income Avl. to Common (TTM) | -26.57M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -111.08% | |||
| EPS Diluted (TTM) | -0.39 | |||
| EPS Diluted Growth (Q YOY) | -94.75% | |||
| Balance Sheet | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 11.76M | |||
| Cash Per Share (Q) | $0.17 | |||
| Total Current Assets (Q) | 12.79M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 7.72M | |||
| Current Ratio (Q) | 2.485 | |||
| Book Value Per Share (Q) | $0.11 | |||
| Total Assets (Q) | 12.97M | |||
| Total Current Liabilities (Q) | 5.15M | |||
| Total Debt (Q) | 122.90K | |||
| Total Liabilities (Q) | 5.25M | |||
| Total Common Equity (Q) | 7.72M | |||
| Cash Flow | CRDL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -19.10K | |||
| Cash from Financing (TTM) | 100.10K | |||
| Net Change in Cash (TTM) | -18.13M | |||
| Levered Free Cash Flow (TTM) | -8.93M | |||
| Cash from Operations (TTM) | -19.07M | |||
